LSC17 score measured by the LDT is strongly associated with survival outcomes. (A) Plot showing LSC17 scores of 306 patients with AML from PM measured by the original research assay²  and by the LSC17 LDT. Each dot represents 1 patient sample. R, Spearman correlation coefficient. (B-C) Kaplan-Meier estimates of overall (B) and relapse-free (C) survival of 306 patients in the PM AML cohort according to LSC17 scores measured by the LDT and classified as high (above median) or low (below median). The median LSC17 score for the cohort was 0.51.